OTC · Healthcare
ELITE PHARMACEUTICALS INC /NV/ (ELTP)
As-reported financials and recent SEC filings for ELITE PHARMACEUTICALS INC /NV/, latest fiscal period FY2026. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$148.9M
Net income
$44.9M
Net margin
30.1%
Diluted EPS
$0.03
ROE
45.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M | $32.3M |
| Gross profit | $75.0M | $40.1M | $26.4M | $16.6M | $14.8M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.7M | $5.1M |
| Net income | $44.9M | $-4.3M | $20.1M | $3.6M | $8.9M |
| Diluted EPS | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-29
View on EDGAR →10-K2026-06-29
View on EDGAR →8-K2026-06-23
View on EDGAR →8-K2026-06-15
View on EDGAR →8-K2026-06-01
View on EDGAR →UPLOAD2026-04-14
View on EDGAR →8-K2026-04-02
View on EDGAR →CORRESP2026-03-18
View on EDGAR →Largest Healthcare peers
Go deeper on ELTP
Search ELITE PHARMACEUTICALS INC /NV/’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.